References
- Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T. Epidemiology of Dupuytren's disease: clinical, serological and social assessment. The Reykjavik Study. J Clin Epidemiol 2000; 53: 291–6
- Luck V. Dupuytren's contracture. J Bone Joint Surg 1959; 41A: 635–64
- Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg 2006; 31A: 204–10
- Wilbrand S, Ekbom A, Gerdin B. A cohort study linked increased mortality in patients treated surgically for Dupuytren's contracture. J Clin Epidemiol 2005; 58: 68–74
- Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999; 15: 21–34
- Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg 2005; 30B: 557–62
- Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392–401
- Bowley E, O'Gorman DB, Gan BS. Beta-catenin signaling in fibroproliferative disease. J Surg Res 2007; 138: 141–50
- O'Gorman DB, Wu Y, Seney S, Zhu RD, Gan BS. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's Disease. J Negat Results Biomed 2006; 30: 5–13
- Varallo VM, Gan BS, Seney S, et al. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003; 22: 3680–4
- Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 2005; 29: 653–9
- Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18: 68–74
- Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151: 329–34
- Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18: 6615–20
- Aruga J. The role of ZIC genes in neural development. Mol Cell Neurosci 2004; 26: 205–21
- Yokota N, Aruga J, Takai S, et al. Predominant expression of human ZIC in cerebellar granule cell lineage and medulloblastoma. Cancer Res 1996; 56: 377–83
- Merzdorf CS, Sive HL. The ZIC1 gene is an activator of Wnt signaling. Int J Dev Biol 2006; 50: 611–7
- Pourebrahim R, Van Dam K, Bauters M, et al. ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. FEBS Lett 2007; 581: 5122–6
- Montgomery E, Lee JH, Abraham SC, Wu TT. Superficial fibromatosis are genetically distinct from deep fibromatoses. Mod Pathol 2001; 14: 695–701
- Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51: 509–14
- Ishiguro A, Inoue T, Mikoshiba K, Aruga J. Molecular properties of Zic4 and Zic5 proteins: functional diversity within Zic family. Biochem Biophys Res Commun 2004; 324: 302–7
- Taipale J, Beachy PA. The hedgehog and Wnt signaling pathways in cancer. Nature 2001; 411: 349–54
- Van den Brink GR, Hardwick JC. Hedgehog Wnteraction in colorectal cancer. Gut 2006; 55: 912–4
- Mizugishi K, Aruga J, Nakata K, Mikoshiba K. Molecular properties of zic proteins as transcriptional regulators and their relationship to GLI proteins. J Biol Chem 2001; 276: 2180–8
- Seyhan H, Kopp J, Schultze-Mosgau S, Horch RE. Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. Plast Reconstr Surg 2006; 117: 1248–52